Equities

Harvard Apparatus Regenerative Technology Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
HRGN:QBB

Harvard Apparatus Regenerative Technology Inc

Actions
  • Price (USD)1.80
  • Today's Change0.12 / 7.14%
  • Shares traded1.36k
  • 1 Year change-34.55%
  • Beta-0.1227
Data delayed at least 15 minutes, as of Feb 06 2026 14:56 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Harvard Apparatus Regenerative Technology, Inc. is a clinical-stage biotechnology company focused on the development of regenerative medicine treatments for disorders of the gastro-intestinal system and other organs that result from cancer, trauma or birth defects. The Company's technology is based on its cell-therapy platform that uses a patient’s own stem cells to regenerate and restore function to damaged organs. The Company is advancing its Cellspan esophageal implant product candidate through an Investigator-Initiated Trial targeting pediatric patients with Esophageal Atresia. Its biocompatible scaffold component of its esophageal implant is constructed primarily of thin polyurethane fibers. Its other product candidates in development pipeline are targeted at the reconstruction of the colon and uterus wound repair. The Company, through its subsidiary, Harvard Apparatus Regenerative Technology Limited, is focused on personal healthcare, including dietary supplements.

  • Revenue in USD (TTM)743.00k
  • Net income in USD-6.53m
  • Incorporated2012
  • Employees8.00
  • Location
    Harvard Apparatus Regenerative Technology Inc84 October Hill Road Suite 11HOLLISTON 01746United StatesUSA
  • Phone+1 (774) 233-7300
  • Fax+1 (774) 233-7302
  • Websitehttps://hregen.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Exicure Inc0.00-9.23m27.15m8.00--3.92-----3.07-3.070.001.090.00----0.00-71.27-44.45-94.78-60.08-------259.52----0.00-----17.3442.65------
Raphael Pharmaceutical Inc0.00-1.40m27.48m0.00---------0.0723-0.07230.00-0.06440.00-------4,831.04-----------------86.56---------13.02------
Marker Therapeutics Inc4.69m-14.30m27.68m5.00--1.51--5.90-1.23-1.230.36831.100.2876--3.90938,996.00-87.60-57.72-110.67-69.11-----304.54-761.28----0.00--99.0698.6323.60------
Promis Neurosciences Inc0.00-29.28m28.20m6.00--3.07-----18.62-18.620.004.270.00-------127.41-85.65-188.18-145.08-------3,184,250.00----0.00------121.03------
Lantern Pharma Inc0.00-18.92m28.63m24.00--2.95-----1.75-1.750.000.86840.00----0.00-86.16-32.94-104.31-34.72------------0.00-------30.20--17.11--
Outlook Therapeutics Inc1.51m-62.42m28.67m17.00------19.04-1.61-1.610.0432-0.59730.0635----88,548.23-263.36-240.08----70.78---4,146.95-22,354.500.3067-200.54--------17.17------
Palatin Technologies Inc8.85m-4.81m28.68m29.00--39.41--3.24-13.52-13.5212.390.40731.47----305,087.90-79.90-79.95---118.700.0091.70-54.32-1,326.05----0.00---100.00--41.80------
Harvard Apparatus Regenertv Tchnlgy Inc743.00k-6.53m28.84m8.00--18.56--38.82-0.4029-0.40290.04590.09050.18919.21371.5092,875.00-166.09-292.39-227.59-1,068.0616.29---878.20-6,677.861.83--0.00--317.48--14.30------
Passage Bio Inc0.00-45.26m28.96m60.00--0.9305-----14.47-14.470.009.790.00----0.00-48.69-49.32-61.70-53.58------------0.00------36.54---54.23--
AN2 Therapeutics Inc0.00-33.99m29.05m22.00--0.4805-----1.13-1.130.002.210.00----0.00-41.21-53.41-45.91-58.50------------0.00------20.72------
Werewolf Therapeutics Inc0.00-72.84m29.42m39.00--0.9674-----1.62-1.620.000.62640.00----0.00-66.32-33.10-76.84-36.81-------593.05---54.290.4829---90.55---88.70---0.919--
NextCure Inc0.00-58.01m29.72m43.00--1.26-----24.19-24.190.008.840.00----0.00-89.28-27.70-105.20-28.91-------1,336.59----0.00------11.27---32.45--
Reviva Pharmaceuticals Holdings Inc0.00-22.76m29.80m14.00--5.40-----0.4722-0.47220.000.04720.00----0.00-207.23------------------0.00------23.79------
Rein Therapeutics Inc0.00-58.89m29.97m11.00--24.19-----2.63-2.630.001.840.00----0.00-74.57-64.62-80.38-71.24------------0.00-------299.71------
VolitionRX Ltd1.47m-22.88m30.33m85.00------20.61-0.229-0.2290.0147-0.3160.1539--4.7417,317.88-241.07-122.29---283.19-----1,566.40-5,826.45---15.03----59.10135.3023.65--2.34--
Data as of Feb 06 2026. Currency figures normalised to Harvard Apparatus Regenerative Technology Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.